IL303100A - 5'-O-phenylacetyluridine and therapeutic use - Google Patents

5'-O-phenylacetyluridine and therapeutic use

Info

Publication number
IL303100A
IL303100A IL303100A IL30310023A IL303100A IL 303100 A IL303100 A IL 303100A IL 303100 A IL303100 A IL 303100A IL 30310023 A IL30310023 A IL 30310023A IL 303100 A IL303100 A IL 303100A
Authority
IL
Israel
Prior art keywords
compound
condition
mammalian subject
uridine
subject
Prior art date
Application number
IL303100A
Other languages
English (en)
Hebrew (he)
Inventor
Garcia Rolando Alejandro Garcia
Joel A Saydoff
David Michael Simpson
Borstel Reid Warren Von
Original Assignee
Wellstat Therapeutics Corp
Garcia Rolando Alejandro Garcia
Joel A Saydoff
David Michael Simpson
Borstel Reid Warren Von
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp, Garcia Rolando Alejandro Garcia, Joel A Saydoff, David Michael Simpson, Borstel Reid Warren Von filed Critical Wellstat Therapeutics Corp
Publication of IL303100A publication Critical patent/IL303100A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/067Pyrimidine radicals with ribosyl as the saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
IL303100A 2020-12-01 2021-11-30 5'-O-phenylacetyluridine and therapeutic use IL303100A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063119764P 2020-12-01 2020-12-01
PCT/US2021/061053 WO2022119784A1 (en) 2020-12-01 2021-11-30 5'-o-phenylacetyluridine and therapeutic use

Publications (1)

Publication Number Publication Date
IL303100A true IL303100A (en) 2023-07-01

Family

ID=81854225

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303100A IL303100A (en) 2020-12-01 2021-11-30 5'-O-phenylacetyluridine and therapeutic use

Country Status (16)

Country Link
US (1) US20230416292A1 (https=)
EP (2) EP4255563B1 (https=)
JP (1) JP2023551467A (https=)
KR (1) KR20230112118A (https=)
CN (1) CN116782912A (https=)
AU (1) AU2021391411A1 (https=)
BR (1) BR112023010517A2 (https=)
CA (1) CA3199559A1 (https=)
DK (1) DK4255563T3 (https=)
FI (1) FI4255563T3 (https=)
IL (1) IL303100A (https=)
LT (1) LT4255563T (https=)
MX (1) MX2023006343A (https=)
PL (1) PL4255563T3 (https=)
PT (1) PT4255563T (https=)
WO (1) WO2022119784A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4210709T (pt) 2020-09-14 2026-02-04 Pharma Cinq Llc 2¿,3¿‐diacetiluridina substituída com acetoacetilo na posição 5¿
TW202317144A (zh) * 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346108A3 (en) * 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
JP2526414B2 (ja) 1994-05-20 1996-08-21 工業技術院長 制ガン剤エステル化合物及びその製造方法
JP4408450B2 (ja) * 1994-07-01 2010-02-03 ウェルスタット セラピューティクス コーポレイション 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体
EP1808177B1 (en) * 1999-02-23 2018-08-08 The Regents of The University of California Methods of treatment of mitochondrial disorders
SI2153870T1 (sl) * 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
PT2922576T (pt) * 2012-11-21 2018-01-24 Horizon Therapeutics Llc Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática
PL3182980T3 (pl) * 2014-08-19 2021-04-19 Wellstat Therapeutics Corporation Leczenie chorób niedoboru glikozylacji
AU2019215105B2 (en) * 2018-02-01 2024-12-19 Pharma Cinq, Llc Compositions and devices for systemic delivery of uridine
WO2022089612A1 (zh) * 2020-10-30 2022-05-05 上海岸阔医药科技有限公司 尿苷衍生物在制备药物中的应用

Also Published As

Publication number Publication date
PL4255563T3 (pl) 2026-04-20
EP4255563B1 (en) 2025-12-31
WO2022119784A1 (en) 2022-06-09
JP2023551467A (ja) 2023-12-08
AU2021391411A1 (en) 2023-07-20
EP4711007A2 (en) 2026-03-18
PT4255563T (pt) 2026-03-24
MX2023006343A (es) 2023-06-12
CN116782912A (zh) 2023-09-19
BR112023010517A2 (pt) 2024-02-06
KR20230112118A (ko) 2023-07-26
EP4255563A1 (en) 2023-10-11
FI4255563T3 (fi) 2026-03-13
EP4711007A3 (en) 2026-04-01
AU2021391411A9 (en) 2024-07-18
CA3199559A1 (en) 2022-06-09
EP4255563A4 (en) 2024-09-11
DK4255563T3 (da) 2026-03-16
LT4255563T (lt) 2026-04-10
US20230416292A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
CN1191835C (zh) 嘧啶基核苷的制药用途
JP3474073B2 (ja) ウリジンまたはシチジンのアシル誘導体を含有する医薬組成物
JP2637534B2 (ja) アシルデオキシリボヌクレオシド誘導体およびその使用
EP0601322A2 (en) Adenosindeaminase inhibitor
EP3478276B1 (en) Methods for inhibiting conversion of choline to trimethylamine (tma)
EP4255563B1 (en) 5'-O-PHENYLACETYLURIDINE AND THERAPEUTIC USE
EP4714442A2 (en) Prodrug of pyrrolidone derivatives as glucokinase activator
CN111635309B (zh) 一种新型解热镇痛药物及其制备方法和用途
CN111635315B (zh) 一种解热镇痛药物及其制备方法和用途
EP0780125B1 (en) Use of hydantoin derivatives for the preparation of a medicament for the treatment of dieases associated with the presence of active oxygen and free radicals
HUE027711T2 (en) An aqueous formulation of improved stability of (E) -4-carboxystyril-4-chlorobenzylsulfone
JP2001511447A (ja) L−カルニチンまたはアルカノイルl−カルニチンおよび長鎖アルカノイルを含む組成物
US20230357304A1 (en) 2′,3′-Diacetyluridine Substituted With Acetoacetyl at the 5′ Position
US20030212130A1 (en) Creatine ester anti-inflammatory compounds and formulations
EP1781294B1 (en) Composition for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
CS209856B2 (en) Method of making the new derivatives of the aminoacids
US6743782B1 (en) Acyl deoxyribonucleoside derivatives and uses thereof
EP0617959A1 (en) Pharmaceutical for the treatment of skin disorders
JPH07118156A (ja) アデノシンデアミナーゼ阻害剤
US4080442A (en) Disaccharide derivatives used in the treatment of hepatic diseases
JPH01199961A (ja) タウリン誘導体、その製法及びこれを含有する薬剤組成物
US6472430B2 (en) Amino thioxomethyl amino oxyacetic acid derivatives
CS209860B2 (cs) Způsob výroby nových derivátů aminokyselin
JPH06135837A (ja) アデノシンデアミナーゼ阻害剤
JPS63258421A (ja) 糖ラクタムを含有する抗炎症剤